Concepedia

Comparative Effectiveness Of Formulations

Comparative Effectiveness of Formulations is a research framework in clinical therapeutics that systematically evaluates and contrasts the clinical outcomes, efficacy, and safety profiles of different pharmaceutical formulations of pancreatic enzyme products to determine relative therapeutic equivalence or superiority under real-world or controlled conditions.

72

Publications

3K

Citations

409

Authors

224

Institutions

Publications per year

2017–2026

13

Parents

Publications

72

A randomized multicenter clinical trial comparing isosmolar Icodextrin with hyperosmolar glucose solutions in CAPD

Chandra D. Mistry, Ram Gokal, Elizabeth Peers et al. · Kidney International · 1994 · 325 citations · Full text

, , +9

Curcumin and Gemcitabine in Patients With Advanced Pancreatic Cancer

Ron Epelbaum, Moshe Schaffer, B. Vizel et al. · Nutrition and Cancer · 2010 · 279 citations

, , +13

GUIDELINES ON EVALUATION OF SIMILAR BIOTHERAPEUTIC PRODUCTS (SBPs)

English Only · 2009 · 244 citations

, , +12

A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide11Ms. Boyle, Dr. Ghosh, and Dr. Adamsons were employees of Merck & Co., Inc, the manufacturer of timolol and dorzolamide, at the time this study was conducted. COSOPT and TRUSOPT are trademark products of Merck & Co., Inc, Whitehouse Station, New Jersey. The other authors have no proprietary interest in timolol, dorzolamide, or Merck.

Janet E Boyle, Kalyan Ghosh, David K. Gieser et al. · Ophthalmology · 1998 · 150 citations

, , +8

DURAbility of Basal Versus Lispro Mix 75/25 Insulin Efficacy (DURABLE) Trial 24-Week Results

John B. Buse, Bruce H. R. Wolffenbuttel, William H. Herman et al. · Diabetes Care · 2009 · 126 citations · Full text

, , +15

1–5 of 72

Authors

409

  1. RE
    Richard E. Pratley

    Translational Research Institute for Metabolism and Diabetes, United States

    2 publications · 43 citations

    2

    h-index

  2. SM
    Sherry Martin

    Eli Lilly (United States), United States

    2 publications · 138 citations

    2

    h-index

  3. EF
    Edward Franek

    Polish Academy of Sciences, Poland

    2 publications · 89 citations

    2

    h-index

  4. LE
    Lars Endahl

    Novo Nordisk (Denmark), Denmark

    2 publications · 89 citations

    2

    h-index

  5. JW
    Jianping Weng

    Sun Yat-sen University, China

    2 publications · 89 citations

    2

    h-index

1–5 of 409

Institutions

224

  1. Eli Lilly (United States)

    Indianapolis, United States

    3 h-index

    11 publications

    741 citations

  2. Novo Nordisk (Denmark)

    Copenhagen, Denmark

    3 h-index

    10 publications

    353 citations

  3. University of California San Diego

    San Diego, United States

    2 h-index

    3 publications

    73 citations

  4. Dallas Diabetes Research Center

    Dallas, United States

    2 h-index

    2 publications

    60 citations

  5. University of Naples Federico II

    Naples, Italy

    2 h-index

    4 publications

    76 citations

  6. Roche (Switzerland)

    Basel, Switzerland

    2 h-index

    3 publications

    70 citations

  7. La Roche College

    Pittsburgh, United States

    2 h-index

    2 publications

    50 citations

  8. Brigham and Women's Hospital

    Boston, United States

    2 h-index

    2 publications

    88 citations

1–8 of 224

Venues

  1. Diabetes Obesity and Metabolism

    8 publications · 201 citations

    8

    h-index

  2. PubMed

    Repository · 5 publications · 114 citations

    5

    h-index

  3. Alimentary Pharmacology & Therapeutics

    4 publications · 139 citations

    4

    h-index

  4. Clinical Therapeutics

    2 publications · 79 citations

    2

    h-index

  5. Scandinavian Journal of Gastroenterology

    2 publications · 43 citations

    2

    h-index

1–5